- Home
- Equipment
- usa new york
- tumor cells
Show results for
Refine by
Tumor Cells Equipment Supplied In Usa New York
22 equipment items found
Manufactured by:Rarecells Diagnostics SAS based inParis Cedex 06, FRANCE
ISET, Isolation by SizE of Tumor Cells, is based on the antibody-independent whole blood filtration approach for CTCs and micro-emboli isolation. The solution relies on the larger size of all types of CTCs as compared to the majority of leukocytes. ISET system successfully captures CTCs that are presenting, by definition, heterogeneous phenotypic ...
Manufactured by:Creative Peptides based inNew York, NEW YORK (USA)
We are dedicated to offering custom peptide synthesis, process development, GMP manufacturing as well as catalog products for customers in industry and research area. We provide Z-DEVD-FMK. Z-DEVD-FMK is a cell-permeable, irreversible inhibitor of Caspase-3/CPP32. It is also an irreversible inhibitor of Caspase-6, Caspase-7, caspase-8, and Caspase-10. Z-DEVD-FMK has been shown to ...
Manufactured by:IN8Bio Inc. based inNew York, NEW YORK (USA)
INB-300, our DeltEx DRI CAR-T, is a preclinical product candidate combining our expertise in gamma-delta T cells, our DRI technology and a novel CAR-directed against the Cholotoxin peptide. Chlorotoxin binds to GBM tumor cells and has been previously utilized as a tumor paint in this setting. Chlorotoxin can also bind to other ...
Manufactured by:Celyad Oncology based inMont-Saint-Guibert, BELGIUM
CYAD-101 is an investigational, non-gene edited allogeneic (from healthy donor derived) CAR T candidate engineered to co-express the chimeric antigen receptor based on NKG2D, a receptor expressed on natural killer (NK) cells that binds to eight stress-induced ligands (NKG2DL) expressed by a broad range of tumor cells and the novel inhibitory ...
Manufactured by:Rarecells Diagnostics SAS based inParis Cedex 06, FRANCE
In 2019, 1,762,450 new cancer cases and 606,880 cancer deaths are projected to occur in the United States. It is estimated that metastasis is the primary cause of 90% of all cancer-related deaths. Circulating Tumor Cells (CTCs) detection and analysis are the foundation of non-invasive tests that can be used repeatedly to support early detection, prognosis, ...
Manufactured by:Celyad Oncology based inMont-Saint-Guibert, BELGIUM
CYAD-02 is an investigational CAR T therapy that engineers an all-in-one vector approach in patient’s T cells to express both (i) the NKG2D chimeric antigen receptor, a receptor expressed on natural killer (NK) cells that binds to eight stress-induced ligands (NKG2DL) expressed on tumor cells, and (ii) short hairpin RNA ...
Manufactured by:Scopus BioPharma based inNew York, NEW YORK (USA)
Our licensed gene therapy, CO-sTiRNA™, is a dual-action STAT3 inhibitor. STAT3 is a gene that drives tumor cell growth and anti-tumor immune suppression. CO-sTiRNA™ is a highly selective and targeted gene therapy that silences the activity of the STAT3 gene by way of RNA interference. CO-sTiRNA™ also stimulates TLR9 receptors to ...
Manufactured by:Creative Peptides based inNew York, NEW YORK (USA)
Thymosin β15 is a small actin-binding protein upregulated in highly metastatic rat prostate cancer cells, relative to low metastatic cells.http://www.creative-peptides.com/product/thymosin-item-10-101-100-109.html ...
Manufactured by:Celyad Oncology based inMont-Saint-Guibert, BELGIUM
CYAD-203 is a preclinical, non-gene edited allogeneic CAR T candidate and our first armored CAR T candidate engineered to co-express the cytokine interleukin-18 (IL-18) with the NKG2D CAR receptor. IL-18 is a proinflammatory cytokine that directly potentiates the anti-cancer activity of CAR T cells while also altering the balance of pro- and anti-inflammatory ...
Manufactured by:UroGen Pharma, Inc. based inPrinceton, NEW YORK (USA)
UGN-301 is UroGen’s in-licensed anti-CTLA-4 antibody (zalifrelimab). UGN-201 is our proprietary formulation of imiquimod, a toll-like receptor 7 (TLR 7) agonist. When combined, these medicines stimulate both the innate (UGN-201) and adaptive (UGN-301) immune responses, both of which are important for fully harnessing the power of the immune system to fight ...
Manufactured by:ENB Therapeutics based inNew York, NEW YORK (USA)
ETBR on the luminal surface of tumor blood vessels, creates a barrier to transendothelial migration and homing of T-cells from the vessel to the tumor by downregulating ICAM-1 (an adhesion molecule). ETBRI blockers restore ICAM-1 expression which is required for T-cells to leave the circulation and infiltrate the ...
Manufactured by:Creative Bioarray based inShirley, NEW YORK (USA)
Human (Parental) Brain Cancer Stem Cell (Plated cells are also available). 120 Population doublings or up to 12 passages. One million viable cells upon thawing of frozen cells, frozen vial of cells shipped in dry-ice. Cell Cultures from single donors, 1000 different cell cultures available, please indicate which lots you require from the 1000 donors. Source: Human Parental Brain Cancer Tissue ...
Manufactured by:Tactiva Therapeutics based inBuffalo, NEW YORK (USA)
Adoptive Cell Transfer (ACT) is a form of immunotherapy that targets tumors specifically and potently by utilizing large numbers of a patient’s own immune cells to target and destroy cancer cells. Typically, starting with a few immune cells derived from the patient’s blood, billions of ...
Manufactured by:Mesothelioma + Asbestos Awareness Center based inSyracuse, NEW YORK (USA)
Lung cancer is one of the most common cancers, and researchers estimate about 3 – 4% of all cases can be attributed to asbestos ...
Manufactured by:Hemogenyx Pharmaceuticals plc based inLondon, UNITED KINGDOM
Hemogenyx Pharmaceuticals utilizes postnatal human hemogenic endothelial cells (Hu-PHEC cells), discovered by Hemogenyx Pharmaceuticals’ Co-Founder Dr Vladislav Sandler, to generate cancer-free hematopoietic stem cells (HSC) for use in transplants to treat blood cancers with superior results. A patent for Dr Sandler’s work was issued in the US in February ...
Manufactured by:Pluristem Therapeutics Inc. based inHaifa, ISRAEL
PLX-Immune are cells that have been induced with tumor necrosis factor alpha (TNF-a) and interferon-gamma (IFN-g), to transiently alter their secretion profile. The product has been evaluated in pre-clinical studies and a peer-reviewed article in the journal Scientific Reports, from Nature, was published which examined the effect of the cells in ...
by:Stemline Therapeutics, Inc. based inNew York, NEW YORK (USA)
CD123 is expressed on multiple malignancies including BPDCN, AML, certain myeloproliferative neoplasms (MPNs), myelodysplastic syndrome (MDS), chronic myeloid leukemia (CML), B-cell acute lymphoid leukemia (B-ALL), hairy cell leukemia, and Hodgkin’s and certain non-Hodgkin’s lymphomas. In addition to expression on tumor bulk, CD123 ...
by:Stemline Therapeutics, Inc. based inNew York, NEW YORK (USA)
XPO1 has been shown to regulate nuclear export of many of the major tumor suppressor proteins and oncogenic cell growth regulators. Overexpression of XPO1 has been reported in many cancer types and is associated with aggressive tumor behavior and poor patient prognosis. Inhibition of XPO1 has been shown to restore tumor ...
Manufactured by:Hemogenyx Pharmaceuticals plc based inLondon, UNITED KINGDOM
Hemogenyx Pharmaceuticals has constructed Chimeric Antigen Receptor (CAR) programmed T cells, termed HEMO-CAR-T, for the potential treatment of Acute Myeloid Leukemia (AML). HEMO-CAR-T is made using Hemogenyx’s proprietary humanised monoclonal antibody against a target on the surface of AML ...
Manufactured by:IN8Bio Inc. based inNew York, NEW YORK (USA)
Our DeltEx platform has enabled a deep pipeline of preclinical and clinical product candidates, which are designed to effectively target and potentially eradicate disease, to improve patient ...